Table 3: Highlights of MSC therapy outcomes from published
clinical trial reports (Jan., 2011- Mar., 2016).
MSC source |
Indication |
Phase |
No. of patients |
Route of
administration |
Outcome |
References |
Auto-BMSC |
ALS |
I |
19 |
Intrathecal |
Safe |
[74] |
Auto-BMSC |
ALS |
I |
7 |
Intrathecal |
Safe |
[75] |
Auto-BMSC |
Spinal cord injury |
I/II |
11 |
Lumbar puncture |
Safe, variable
improvement |
[76] |
Auto-BMSC |
Spinal cord injury |
I |
14 |
Intra-lesional |
Safe, variable improvement |
[77] |
Auto-BMSC |
Degenerative disc
disease |
I |
10 |
Intra-nucleus
pulposus |
Rapidly improved |
[78] |
Auto-BMSC |
Coronary artery disease |
I/II |
31 |
Intra-myocardium |
Safe, significantly improved |
[79] |
Auto-BMSC |
Acute myocardial
infarction |
II/III |
58 |
Intra-coronary |
Safe, modestly
improved |
[80] |
Auto-BMSC |
Alcoholic liver cirrhosis |
II |
11 |
IV |
Safe, improved |
[81] |
Auto-BMSC |
HCV-induced
cirrhosis |
II |
15 |
IV |
Safe, partially
improved |
[82] |
Auto-BMSC |
MS |
II |
5 |
IV |
Safe |
[83] |
Auto-BMSC |
MS |
I/II |
10 |
IV |
Safe, improved |
|
Auto-BMSC |
OA, knee |
I/II |
12 |
Intra-articular |
Safe, significantly improved |
[86] |
Auto-BMSC |
Kidney allograft |
I |
6 |
IV |
Safe, improved |
[87] |
Auto-BMSC&
BMNCs |
Critical limb ischemia |
II |
26 |
Intramuscular |
Safe, significantly improved |
[88] |
Auto-BMSC/ MSC |
Ischemic
cardiomyopathy |
I/II |
65 |
Transendocardium |
Safe |
[89] |
Auto-/Allo-BMSC |
Ischemic cardiomyopathy |
I/II |
30 |
Transendocardium |
Safe, improved |
[90] |
Auto-AMSC |
Crohn’s disease |
II |
41 |
Intra-fistula tract |
Safe, improved |
[91] |
Auto-AMSC |
Idiopathic pulmonary fibrosis |
I |
14 |
Intra-endobronchial |
Safe |
[92] |
Auto-AMSC |
OA, knee |
I/II |
18 |
Intra-articular |
Safe, improved |
[93] |
Auto-AMSC |
Anal fistula |
III |
124 |
Intra-fistula tract |
Safe, improved |
[94] |
Auto-MSC |
Spinal cord injury |
III |
16 |
Intramedullary/Intradural
space |
Safe, weak efficacy |
[95] |
Allo-BMSC |
SLE |
I/II |
15 |
IV |
Improved |
|
Allo-BMSC |
ARDS |
I |
9 |
IV |
Safe |
[98] |
Allo-BMSC |
Critical limb ischemia |
I/II |
20 |
Intramuscular |
Safe, improved |
[99] |
Allo-BMSC |
OA, knee |
I/II |
30 |
Intra-articular |
Safe, significantly
improved |
[100] |
Allo-BMSC |
aGvHD |
II |
25 |
IV |
Safe |
[101] |
Allo-BMSC |
GvHD |
II |
37 |
IV |
Safe, improved |
[102] |
Allo-BMSC |
GvHD |
I |
40 (15 children) |
IV |
Safe, variable improvements |
[25] |
Allo-BMSC (JR-031) |
aGvHD |
II/III |
25 |
IV |
Variable
improvements |
[103] |
Allo-UCMSC |
SLE |
I/II |
40 |
IV |
Variable improvements |
|
Allo-UCB-MSC |
BPD (Preterm) |
I |
9 (preterm infants) |
Intratracheal |
Safe |
[105] |
Allo-UCB-MSC |
Critical limb ischemia |
I |
8 |
Intramuscular |
Safe |
[106] |
Allo-UCB-MNCs/
UCMSC |
Autism |
I/II |
23 |
IV + Intrathecal |
Safe, improved |
[107] |
Allo-PL-MSC |
Idiopathic pulmonary fibrosis |
I |
8 |
IV |
Safe |
[108] |
Allo-PL-MSC
(PDA-001) |
MS |
I |
16 |
IV |
Safe |
[109] |
Allo-MPCs |
Nonischemic heart failure |
II |
60 |
Transendocardium |
Safe |
[110] |
Allo-MPACs |
aGvHD |
I |
36 |
IV |
Safe |
[111] |
Allo-MSC |
Crohn’s disease |
II |
15 |
IV |
Variable improvements |
[112] |
Allo-MSC |
GvHD |
I/II |
18 |
IV |
Variable
improvements |
[113] |
Allo-MSC (Prochymal) |
aGvHD |
I |
12 (children) |
IV |
Safe, variable improvements |
[114] |
Allo-AMSC |
Crohn’s disease |
I/II |
24 |
Intra-lesional |
Safe, improved |
[115] |
Allo-WJ-MSC |
Type 2 diabetes mellitus |
I/II |
22 |
IV + Intrapancreatic
endovascular injections |
Safe, improved |
[116] |
Lxmyelocel-T |
Critical limb
ischemia |
II |
72 |
Leg injections |
Safe, prolonged
treatment failure |
[117] |
Abbreviations:
Allo: allogeneic; Auto: autologous; AMSC: adipose tissue-derived mesenchymal stem cells; BMSC: bone marrow-derived mesenchymal stem cells; MSC: mesenchymal
stem cells; MNCs: mononuclear cells; MPCs: mesenchymal
progenitor cells; MPACs: multipotent adult progenitor
cells; UC-: umbilical cord-derived; UCB-: umbilical cord blood-derived; PL-:
placenta-derived; WJ-: Wharton’s jelly-derived; ALS: amyotrophic lateral
sclerosis; ARDS: acute respiratory distress syndrome; BPD: bronchopulmonary
dysplasia; MS: multiple sclerosis; OA: osteoarthritis; SLE: systemic lupus erythematosus; aGvHD: acute
graft-versus-host disease; IV: intravenous; HCV: hepatitis C virus